期刊
JOURNAL OF ALZHEIMERS DISEASE
卷 62, 期 2, 页码 841-854出版社
IOS PRESS
DOI: 10.3233/JAD-171036
关键词
Biomarkers; blood; lyso-PAF; lysophosphatidylcholines; lysophospholipids; mass spectrometry; plasmalogens
资金
- Austrian Science Fund (FWF) [P 24843-B24, P 21950-B20, I2738-B26]
- Ludwig Boltzmann Society, Vienna (Austria)
- Austrian Science Fund (FWF) [I2738] Funding Source: Austrian Science Fund (FWF)
Alzheimer's disease (AD) is the most common neurodegenerative disease and of continuously rising prevalence. The identification of easy-to-measure biomarkers capable to assist in the prediction and early diagnosis of AD is currently a main research goal. Lipid metabolites in peripheral blood of human patients have recently gained major attention in this respect. Here, we analyzed plasma of 174 participants (not demented at baseline; mean age: 75.70 +/- 0.44 years) of the Vienna Transdanube Aging (VITA) study, a longitudinal, population-based birth cohort study, at baseline and after 90 months or at diagnosis of probable AD. We determined the levels of specific choline phospholipids, some of which have been suggested as potential biomarkers for the prediction of AD. Our results show that during normal aging the levels of lysophosphatidylcholine, choline plasmalogen, and lyso-platelet activating factor increase significantly. Notably, we observed similar but more pronounced changes in the group that developed probable AD. Thus, our results imply that, in terms of choline-containing plasma phospholipids, the conversion to AD mimics an accelerated aging process. We conclude that age, even in the comparatively short time frame between 75 and 82.5 years, is a crucial factor in the quest for plasma lipid biomarkers for AD that must be carefully considered in future studies and trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据